BRPI1010119A2 - "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica" - Google Patents

"método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"

Info

Publication number
BRPI1010119A2
BRPI1010119A2 BRPI1010119A BRPI1010119A BRPI1010119A2 BR PI1010119 A2 BRPI1010119 A2 BR PI1010119A2 BR PI1010119 A BRPI1010119 A BR PI1010119A BR PI1010119 A BRPI1010119 A BR PI1010119A BR PI1010119 A2 BRPI1010119 A2 BR PI1010119A2
Authority
BR
Brazil
Prior art keywords
production method
ion exchange
exchange chromatography
antibody composition
composition production
Prior art date
Application number
BRPI1010119A
Other languages
English (en)
Inventor
Bernhard Hilger
Claus Wallerius
Frank Zettl
Josef Burg
Lars Stiens
Thorsten Kaiser
Wolfgang Kuhne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1010119A2 publication Critical patent/BRPI1010119A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1010119A 2009-07-24 2010-07-22 "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica" BRPI1010119A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09009640 2009-07-24
PCT/EP2010/004509 WO2011009623A1 (en) 2009-07-24 2010-07-22 Optimizing the production of antibodies

Publications (1)

Publication Number Publication Date
BRPI1010119A2 true BRPI1010119A2 (pt) 2016-03-15

Family

ID=41381958

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010119A BRPI1010119A2 (pt) 2009-07-24 2010-07-22 "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"

Country Status (12)

Country Link
US (3) US20120177640A1 (pt)
EP (2) EP3404044A1 (pt)
JP (1) JP5540095B2 (pt)
KR (1) KR101498772B1 (pt)
CN (1) CN102471377B (pt)
AU (1) AU2010275774B2 (pt)
BR (1) BRPI1010119A2 (pt)
CA (1) CA2768325C (pt)
IL (1) IL217381A (pt)
MX (1) MX2012000841A (pt)
SG (1) SG178078A1 (pt)
WO (1) WO2011009623A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
MX357821B (es) * 2010-12-21 2018-07-25 Hoffmann La Roche Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2714713B1 (en) * 2011-05-26 2018-05-09 Dr. Reddy's Laboratories Limited Purification of anti-cd20 antibodies
US8852435B2 (en) 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
EP2791176B1 (en) * 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2890979A1 (en) 2012-11-15 2014-05-22 Genentech, Inc. Ionic strength-mediated ph gradient ion exchange chromatography
CN103217499B (zh) * 2013-01-15 2015-12-02 珠海市丽珠单抗生物技术有限公司 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
KR102202476B1 (ko) * 2013-03-15 2021-01-12 제넨테크, 인크. 세포 배양 배지 및 항체 생산 방법
CA2918052A1 (en) 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015083853A1 (ko) * 2013-12-05 2015-06-11 한화케미칼 주식회사 이성질 항체의 함량 조절을 통한 항체 제조 방법
LT3116891T (lt) * 2014-03-10 2020-03-25 Richter Gedeon Nyrt. Imunoglobulino gryninimas, naudojant išankstinio valymo pakopas
WO2016164708A1 (en) * 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
AR114722A1 (es) * 2018-04-02 2020-10-07 Amgen Inc Composiciones de erenumab y usos de las mismas
CN109293734A (zh) * 2018-09-29 2019-02-01 上海药明生物技术有限公司 一种消除层析中洗脱肩峰的方法
CN113227789A (zh) * 2018-12-30 2021-08-06 豪夫迈·罗氏有限公司 基于pH梯度SPR的结合测定
WO2024090489A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
IL130061A (en) * 1996-11-27 2001-09-13 Genentech Inc Affinity purification of polypeptide on protein a matrix
DK1308455T3 (da) * 1998-05-06 2006-07-31 Genentech Inc Sammensætning omfattende anti-HER2-antistoffer
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
HUE033623T2 (en) * 2002-09-11 2017-12-28 Genentech Inc protein purification
WO2006084111A2 (en) 2005-02-04 2006-08-10 Glaxo Group Limited Optimization of heterologous polypeptide expression
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Also Published As

Publication number Publication date
SG178078A1 (en) 2012-03-29
EP2456789A1 (en) 2012-05-30
WO2011009623A1 (en) 2011-01-27
MX2012000841A (es) 2012-02-28
CN102471377A (zh) 2012-05-23
AU2010275774B2 (en) 2016-03-31
US20160102149A1 (en) 2016-04-14
CA2768325A1 (en) 2011-01-27
IL217381A (en) 2016-04-21
IL217381A0 (en) 2012-02-29
JP2013500244A (ja) 2013-01-07
EP3404044A1 (en) 2018-11-21
US20120177640A1 (en) 2012-07-12
CN102471377B (zh) 2015-04-22
KR20120046274A (ko) 2012-05-09
US20190218305A1 (en) 2019-07-18
JP5540095B2 (ja) 2014-07-02
AU2010275774A1 (en) 2012-01-12
CA2768325C (en) 2019-10-29
KR101498772B1 (ko) 2015-03-04

Similar Documents

Publication Publication Date Title
BRPI1010119A2 (pt) "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"
CY2017021I2 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
BRPI0813514A2 (pt) anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
SMT201500210B (it) Composizioni applicazioni di gel rimovibili per unghie e metodi per il loro uso
BRPI0906435A2 (pt) anticorpos anti-cd79b e imunoconjugados e métodos de uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0820298A8 (pt) composições e métodos de anticorpos anti-vegf
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
BRPI0819280A2 (pt) Preparação de amostra para amostragem ambiental
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0818903A2 (pt) Formulação líquida contendo anticorpo de concentração elevada
DK1896572T3 (da) Fremgangsmåde til fremstilling af organotypiske cellekulturer
BRPI0820819A2 (pt) Formulação de anticorpos
EP2615457A4 (en) REAGENT COMPOSITION FOR NUCLEIC ACID CHROMATOGRAPHY OR IMMUNCHROMATOGRAPHY, METHOD FOR MEASURING BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNCHROMATOGRAPHY, AND KIT FOR MEASURES BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNCHROMATOGRAPHY
BRPI0813140A2 (pt) Composição, método e preparação de ácido biliar sintético
BRPI0922730A2 (pt) formulação de anticorpo
BRPI0913739A2 (pt) Composição líquida, método, e, uso de composição
BRPI0818959A2 (pt) "artigos e métodos para coleta de amostras ambientais"
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0918419A2 (pt) nova formulação anticorpo
EP2222871A4 (en) METHODS OF PERFORMING ULTRA-SENSITIVE IMMUNOASSAY

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.